Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramides by exosomal release
Yoshinari Obata, … , Norikazu Maeda, Iichiro Shimomura
Yoshinari Obata, … , Norikazu Maeda, Iichiro Shimomura
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e99680. https://doi.org/10.1172/jci.insight.99680.
View: Text | PDF
Research Article Cell biology Metabolism

Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramides by exosomal release

  • Text
  • PDF
Abstract

Adiponectin, an adipocyte-derived circulating protein, accumulates in vasculature, heart, and skeletal muscles through interaction with a unique glycosylphosphatidylinositol-anchored cadherin, T-cadherin. Recent studies have demonstrated that such accumulation is essential for adiponectin-mediated cardiovascular protection. Here, we demonstrate that the adiponectin/T-cadherin system enhances exosome biogenesis and secretion, leading to the decrease of cellular ceramides. Adiponectin accumulated inside multivesicular bodies, the site of exosome generation, in cultured cells and in vivo aorta, and also in exosomes in conditioned media and in blood, together with T-cadherin. The systemic level of exosomes in blood was significantly affected by adiponectin or T-cadherin in vivo. Adiponectin increased exosome biogenesis from the cells, dependently on T-cadherin, but not on AdipoR1 or AdipoR2. Such enhancement of exosome release accompanied the reduction of cellular ceramides through ceramide efflux in exosomes. Consistently, the ceramide reduction by adiponectin was found in aortas of WT mice treated with angiotensin II, but not in T-cadherin–knockout mice. Our findings provide insights into adiponectin/T-cadherin–mediated organ protection through exosome biogenesis and secretion.

Authors

Yoshinari Obata, Shunbun Kita, Yoshihisa Koyama, Shiro Fukuda, Hiroaki Takeda, Masatomo Takahashi, Yuya Fujishima, Hirofumi Nagao, Shigeki Masuda, Yoshimitsu Tanaka, Yuto Nakamura, Hitoshi Nishizawa, Tohru Funahashi, Barbara Ranscht, Yoshihiro Izumi, Takeshi Bamba, Eiichiro Fukusaki, Rikinari Hanayama, Shoichi Shimada, Norikazu Maeda, Iichiro Shimomura

×

Figure 4

Adiponectin increases exosome production from T-cadherin–expressing cells.

Options: View larger image (or click on image) Download as PowerPoint
Adiponectin increases exosome production from T-cadherin–expressing cell...
(A–C) Adiponectin (APN) enhanced exosome yields from F2T cells. Serum collected from APN-knockout (AKO) mice treated with adenovirus expressing APN (Ad-APN) or β-galactosidase (Ad-βGal) was mixed to obtain the indicated concentrations of APN. F2T cells were treated with the indicated APN concentrations, and exosomes isolated from conditioned media by differential ultracentrifugation were analyzed by Western blotting (A), acetylcholinesterase (AChE) activity (B), or nanoparticle tracking analysis (C). n = 3 for each experiment. (A) APN increased exosomal T-cadherin (T-cad) and exosomal cargos tested. T-cad (105 and 130 kDa), ALIX (95 kDa), Hsp70 (70 kDa), CD63 (broad 50–100 kDa), MFG-E8 (45 and 55 kDa), and syntenin (32 kDa) bands were quantified, the results of which are shown in the right panel. Representative results of 5 experiments with similar findings. *P < 0.05, **P < 0.01 versus 0 μg/ml APN (unpaired t test). (B) Enzymatic quantification of AChE activities associated with exosome pellets. ***P < 0.001 (unpaired t test). (C) APN increased the number of exosome-sized particles. The mean particle concentration (n = 3) is plotted against the particle size (left panel), with total particle counts (right panel). ***P < 0.001 (unpaired t test). (D) Purified APN analyzed by Coomassie brilliant blue (CBB) stain and Western blot. APN was purified from Ad-APN–injected mouse serum using T-cadherin–conjugated resin. N, nonheating and nonreducing conditions; R, heating and reducing conditions. (E) Comparison of the effects of APN-containing serum and T-cadherin resin–purified APN on exosome production. APN concentrations were adjusted to 3 μg/ml. n = 3. Representative results of 3 experiments with similar findings. *P < 0.05, **P < 0.01 versus 0 μg/ml APN. There was no statistically significant difference between APN-containing serum and purified APN (1-way ANOVA with Tukey’s post hoc test). Data are the mean ± SEM.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts